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Background: Absorbable metal scaffolds (AMS) are attractive as after absorption they
only leave behind the healed, natural vessel without permanent implant, allowing
restoration of vasoreactivity with the potential for vessel remodelling. Magnesium is
an essential element of the human body, thus Magnesium is considered as a potential
alloy for absorption. To overcome the limitations associated with the first generation
of a bare AMS, a Drug (Paclitaxel) Eluting Absorbable Magnesium Scaffold was
developed (DREAMS).
Methods: Between July and December 2010, 46 subjects were enrolled in the first-in-
man BIOSOLVE-I study, assigned to two different cohorts with different follow-up
schedules. Clinical follow-up for both cohorts are at 1, 6, 12, 24 and 36 months,
angiographic follow-up for cohort 1 at 6 months and for cohort 2 at 12 months.
Angiographic assessments are evaluated by an independent core laboratory. The
primary endpoint is Target Lesion Failure (TLF), defined as cardiac death, target vessel
myocardial infarction and clinically driven target lesion failure, at 6 months for cohort
1 and at 12 month for cohort 2.
Results: Of the 46 subjects 34 were male and 12 were female subjects with a mean
age of 65.3 ± 9.7 years ranging from 42 to 80 years. Hyperlipidemia (89%),
hypertension (87%) and history of myocardial infarction (33%) were the major medical
risk factors. Type A (45%), Type B1 (51%) and Type B2 (4%) lesions were treated
with a 3.25 / 16 mm (49%) or a 3.5 / 16 mm (51%) DREAMS. Acute results on all 46
patients enrolled in the BIOSOLVE-I study demonstrate 100% device and 100%
procedure success as well as excellent safety results. Up to six months no cardiac death,
no myocardial infarction and no scaffold thrombosis occurred in any of the subjects.
Target Lesion Failure rate is comparable to other first in man studies.
Conclusion: DREAMS is a safe drug eluting absorbable metal scaffold with a TLF
Rate which is comparable with conventional permanent drug eluting stents in first-in-
man trials. Six- month angiographic assessment is ongoing and QCA results will be
available upon presentation.
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Background: Drug delivery balloons (DDBs) are a new class of medical devices
developed to address the growing US$7B atherosclerosis market. DDBs are designed
to simultaneously open blocked blood vessels while delivering drugs to prevent
restenosis. While clinical results are promising, the drug coating used on current DDBs
is not optimal, resulting in significant drug loss during the procedure, inaccurate dosing,
and poorly defined pharmacokinetics. This has raised concerns within the clinical and
regulatory community regarding the safety and long term efficacy of DDBs.
Methods: A pressure-sensitive bioadhesive coating embedded with drug eluting
nanoparticles has been developed. The robust bioadhesive coating is designed to
transfer upon PTCA balloon inflation. When the balloon is subsequently deflated and
removed, the bioadhesive coating will remain attached to the vessel wall, after which
the tissue-embedded nanoparticles will slowly deliver their therapeutic payload over a
1-4 week period. The bioadhesive will itself also dissolve completely in this time.
Results: The pressure-sensitive bioadhesive coating was evaluated for nanoparticle
penetration, pharmacokinetics, and tissue cytotoxicity in a ex vivo swine artery
bioreactor. Nanoparticle penetration, with the help of the bioadhesive, displayed drug
infiltration greater than >400 microns into the swine aorta artery. Optimized
nanoparticle/bioadhesive films transferred with a high degree of reproducibility, with
less than 1% of the film remaining on the PTCA balloon after inflation.
Conclusion: Drug delivery balloons incorporating a pressure-sensitive bioadhesive
embedded with drug eluting nanoparticles is promising towards treatment of restenosis.
Further development of bioadhesive films is warranted toward a potential therapy in
cardiovascular disease, and other vascular pathologies.
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Background: Permanent polymeric drug-eluting stents (DES) demonstrate some
coronary arterial luminal loss late after implantation (“late catch-up”). In contrast, after
implantation of a bioresorbable everolimus-eluting scaffold (ABSORB, Abbott
Vascular, CA) in the small 30 patient ABSORB Cohort A trial there was luminal
enlargement between 6 months and 2 year follow-up. Cohort B of the ABSORB trial
evaluates the modified ABSORB device that is similar in many aspects but has greater
and longer lasting radial strength while resorbing sufficiently by 12 months to permit
vasomotion indicating that the vessel is no longer caged. If there is absence of “late
catch-up” or even luminal enlargement between 6 months and 2 years for the Cohort
B ABSORB scaffold, this could be an important differentiation from metallic DES.
Methods: The ABSORB Cohort B 101 patients were divided into 2 groups on the basis
of angiographic follow-up timing: Group B1 (45 patients) having this at 6 months and
2 years and Group B2 (56 patients) having this at 1 and 3 years.
Results: Clinical results in all 101 patients showed an ID-MACE rate of 6.9% with no
scaffold thromboses. Angiographic results at 6 months (B1) and 1 year (B2) showed
comparable ABSORB LL compared with XIENCE V Everolimus Eluting Coronary
Stent System in the SPIRIT FIRST First-In-Man trial (0.18mm vs. 0.10mm and
0.27mm vs. 0.23mm, see figure below). The 2-year clinical and angiographic results
for Group B1 from the ABSORB Cohort B trial will be presented.
Conclusion: One year clinical outcome of ABSORB Cohort B showed the scaffold to
be safe; two year follow-up clinical and angiographic data analysis is pending.
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Background: Percutaneous coronary interventions (PCI) are increasingly performed
worldwide to treat patients with coronary artery disease. However, studies regarding
the influence of ethnicity on clinical outcomes after PCI are scarce. In our current
analysis, we evaluate the differences in baseline clinical, angiographic and procedural
characteristics, and 12-month clinical outcomes in patients undergoing non-urgent PCI
in Western Europe and in Asia.
Methods: We analysed all patients enrolled in the worldwide e-HEALING registry
living in Western Europe and Asia. All patients were treated with at least one Genous
stent. The main study outcome was target vessel failure (TVF) at 12-months, defined
as the composite of death or MI and target vessel revascularization.
Results: All 3504 patients, 2873 living in Western Europe and 731 living in Asia, were
assessed in the current analysis. Nearly all baseline clinical and angiographic
characteristics differed significantly between both groups. TVF at 12 months occurred
in 11.4% of the Western Europe patients and in 5.6% of the Asian patients (p<0.01).
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